| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 9th October 2020 | James Arthur Bristol | 19,370 | Open or private sale | $53.35 | $1,033,451.48 |
| 9th October 2020 | James Arthur Bristol | 23,541 | Exercise of derivative | $1.89 | $44,492.49 |
| 9th October 2020 | James Arthur Bristol | 200 | Open or private sale | $55.43 | $11,086.00 |
| 9th October 2020 | James Arthur Bristol | 3,971 | Open or private sale | $54.53 | $216,531.09 |
| 2nd October 2020 | Matthew L Sherman | 2,632 | Payment by withholding | $51.15 | $134,618.11 |
| 1st October 2020 | Michael Douglas Taylor | 20,365 | Exercise of derivative | $1.89 | $38,489.85 |
| 1st October 2020 | Michael Douglas Taylor | 23,886 | Open or private sale | $51.98 | $1,241,596.67 |
| 1st October 2020 | Michael Douglas Taylor | 101,114 | Open or private sale | $51.52 | $5,208,887.71 |
| 1st October 2020 | Michael Douglas Taylor | 104,635 | Exercise of derivative | $1.89 | $197,760.15 |
| 14th September 2020 | Thomas Patrick Kelly | 3,000 | Exercise of derivative | $1.89 | $5,670.00 |
Deciphera Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Deciphera Pharmaceuticals, Inc. develops and manufactures kinase inhibitor treatments for cancer. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Ticker: DCPH
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1654151
Employees: 258
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $155 M (29%)
Inventory, Net: $1 M (0%)
Assets, Current: $633 M (6%)
Property, Plant and Equipment, Net: $10 M (51%)
Assets: $686 M (10%)
Accounts Payable, Current: $13 M (-35%)
Liabilities, Current: $51 M (-14%)
Liabilities: $67 M (-12%)
Common Stock, Value, Issued: $561 Th (8%)
Common Stock, Shares, Issued: $56 M (8%)
Additional Paid in Capital, Common Stock: $1 B (20%)
Retained Earnings (Accumulated Deficit): $628 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $8 Th (-92%)
Stockholders' Equity (Parent): $620 M (0%)
Liabilities and Equity: $686 M (10%)
Revenue: $7 M (0%)
Cost of Revenue: $8 Th (0%)
Research and Development: $46 M (-52%)
Operating Income/Loss: $69 M (-52%)
Other Income, net: $2 M (-59%)
News
What Makes James Bond Great
31st October 2020
Top Stocks To Short As Markets Look To End Month With Losses
31st October 2020
Behind real estate’s surprise 2020 boom and what comes next
31st October 2020
Dunkin' Brands to go private in US$8.76 billion deal by Arby's owner
31st October 2020